HLA-C and neoplasm: Instead of targeting MHC in the conventional way, the modifiable extracellular region serves as a chimeric receptor, which enables the cell to bind any surface antigen of interest, making it a customizable tool to directly target tumor associated markers (Garza Trevino et al., 2023).